Journal: Cerebellum (London, England)

Article Title: Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies

doi: 10.1007/s12311-026-02051-w

Figure Lengend Snippet: Cell viability analysis and USP2 expression in samples treated with ML364 at the IC 50 concentration. A and B Cell viability in D283 Med and USP-13 cells was assessed by using a range of ML364 concentrations. Viability was assessed at 24, 48, or 72 h after treatment. Both cell lines showed a dose- and time-dependent decrease in viability. Two-way ANOVA test. **( p = 0.0028) ****( p < 0.0001). C and D Lower USP2 level (23%) in D283 Med cells. No statistically significant differences were observed between groups. Note: CT = Control group

Article Snippet: For the cell viability assays, D283 Med or USP-13 cells were treated with different ML364 doses ranging from 5 to 150 μM for 24, 48, or 72 h. ML364 (Cat. No.: HY-100900; MedChemExpress), which selectively inhibits the USP2 protein, had previously been diluted in DMSO, according to the manufacturer’s recommendation.

Techniques: Expressing, Concentration Assay, Control

Journal: Cerebellum (London, England)

Article Title: Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies

doi: 10.1007/s12311-026-02051-w

Figure Lengend Snippet: Clonogenic and transwell assays conducted in D283 Med and USP-13 cells treated with ML364. A and B Clonogenic assay showing that lost their ability to form colonies after treatment with ML364. Mann-Whitney test. ****( p < 0.0001). C and D Decreased migration and invasion capacity following treatment with ML364 at the IC 50 concentration. Mann-Whitney test. ****( p < 0.0001). Note: CT = Control group

Article Snippet: For the cell viability assays, D283 Med or USP-13 cells were treated with different ML364 doses ranging from 5 to 150 μM for 24, 48, or 72 h. ML364 (Cat. No.: HY-100900; MedChemExpress), which selectively inhibits the USP2 protein, had previously been diluted in DMSO, according to the manufacturer’s recommendation.

Techniques: Clonogenic Assay, MANN-WHITNEY, Migration, Concentration Assay, Control

Journal: Cerebellum (London, England)

Article Title: Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies

doi: 10.1007/s12311-026-02051-w

Figure Lengend Snippet: Effects of ML364 treatment on SKP2 and p27 protein expression in D283 Med cells. A Densitometric analysis and representative Western blot bands of SKP2 protein levels normalized to Vinculin after ML364 treatment at the IC 50 concentration. B Densitometric analysis and representative Western blot bands of p27 protein levels normalized to Vinculin under the same experimental conditions. Data are expressed as mean ± SD (or SEM). Statistical analysis was performed using the Mann-Whitney test. No statistically significant differences were observed between groups. Note: CT = Control group

Article Snippet: For the cell viability assays, D283 Med or USP-13 cells were treated with different ML364 doses ranging from 5 to 150 μM for 24, 48, or 72 h. ML364 (Cat. No.: HY-100900; MedChemExpress), which selectively inhibits the USP2 protein, had previously been diluted in DMSO, according to the manufacturer’s recommendation.

Techniques: Expressing, Western Blot, Concentration Assay, MANN-WHITNEY, Control